Janney Montgomery Scott LLC Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Janney Montgomery Scott LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,907 shares of the biopharmaceutical company’s stock after buying an additional 2,593 shares during the period. Janney Montgomery Scott LLC’s holdings in Regeneron Pharmaceuticals were worth $25,898,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Seven Eight Capital LP acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $802,000. Scotia Capital Inc. acquired a new position in Regeneron Pharmaceuticals during the third quarter worth approximately $242,000. Royal London Asset Management Ltd. raised its stake in Regeneron Pharmaceuticals by 4.2% during the third quarter. Royal London Asset Management Ltd. now owns 40,581 shares of the biopharmaceutical company’s stock worth $33,395,000 after purchasing an additional 1,652 shares during the period. Royal Bank of Canada boosted its holdings in shares of Regeneron Pharmaceuticals by 4.6% in the 3rd quarter. Royal Bank of Canada now owns 159,933 shares of the biopharmaceutical company’s stock valued at $131,619,000 after purchasing an additional 6,991 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its stake in shares of Regeneron Pharmaceuticals by 8.9% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,000 shares of the biopharmaceutical company’s stock valued at $17,282,000 after buying an additional 1,713 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. Insiders have sold a total of 63,208 shares of company stock valued at $62,514,142 in the last quarter. Insiders own 7.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on REGN shares. Bank of America boosted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Argus increased their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. UBS Group raised their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective for the company. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,027.55.

Regeneron Pharmaceuticals Stock Up 1.0 %

NASDAQ REGN traded up $10.14 during trading hours on Friday, reaching $1,034.23. 418,302 shares of the company traded hands, compared to its average volume of 436,890. The stock has a market capitalization of $113.96 billion, a PE ratio of 30.55, a PEG ratio of 2.12 and a beta of 0.13. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12 month low of $688.52 and a 12 month high of $1,081.17. The company has a 50 day moving average of $998.19 and a two-hundred day moving average of $956.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.